Introduction
The tumor suppressor p53 is an important component of the cellular machinery that responds to genotoxic stresses, particularly DNA damage, to maintain genomic integrity by arresting the cell cycle or by inducing apoptosis (Ko and Prives, 1996; Levine, 1997) . In normal cells, the tumor suppressor p53 protein is found in low levels because of its short half-life (Levine, 1997) . In response to several types of DNA damage, including double-stranded breaks formed by g-irradiation and DNA-repair intermediates formed by UV irradiation, p53 levels are rapidly induced and its transcriptional activity is activated. Although not always the case, there is substantial evidence that much of the biological activity of p53 is achieved through its ability to regulate gene transcription (Buckbinder et al., 1995; El-Deiry et al., 1993; Miyashita et al., 1994a; Miyashita and Reed, 1995; Owen-Schaub et al., 1995) .
The bax gene is known to be transcriptionally regulated by p53 during induction of apoptosis (Buckbinder et al., 1995; Miyashita and Reed, 1995) . Bax is a pro-apoptotic Bcl-2 family member that binds to the anti-apoptotic Bcl-2 protein, and can antagonize its function to block apoptosis (Oltvai et al., 1993) . Induction of Bax also promotes cytochrome c release from the mitochondria, which is inhibited by anti-apoptotic Bcl-2 family members (RosseÂ et al., 1998) , therefore, bax up-regulation is one mechanism whereby p53 induces apoptosis. The biochemical mechanism of Bcl-2 and Bax function, however, remains elusive. Structural studies of Bcl-2 family members have demonstrated similarities to pore-forming domains of bacterial toxins, which has suggested a role in modulation of membrane function (Chou et al., 1999; McDonnell et al., 1999; Minn et al., 1997; Sattler et al., 1997; Schendel et al., 1999) .
Other genes regulated by p53 during apoptosis are IGF-BP3 (Buckbinder et al., 1995) and Fas/Apo-1 (Owen- Schaub et al., 1995) . IGF-BP3 has been shown to block IGF-induced signaling by binding to IGF and preventing its binding to its receptor, and inhibiting IGF activity promotes apoptosis in cells. It has also been reported that p53 can induce the expression of the Fas/Apo-1 gene (Owen-Schaub et al., 1995) . The cell surface receptor, Fas, mediates apoptosis through a cascade of signaling molecules (Nagata, 1997) . Therefore, inducing apoptosis through the Fas pathway would represent another mechanism by which p53 can promote cell death.
We have previously characterized a transformed BRK epithelial cell line (p53A cells) expressing the adenovirus E1A protein and the temperature-sensitive mutant of p53(va1135) (Debbas and White, 1993) . The temperature sensitive p53 mutant is in the mutant conformation at the nonpermissive temperature of 38.58C and is in the wild-type conformation at the permissive temperature of 328C. As reported pre-viously, p53A cells are transformed and proliferate at 38.58C and at 328C undergo p53-dependent cell death by apoptosis (Debbas and White, 1993; Sabbatini et al., 1995b; Thomas and White, 1998) . Previous studies have shown that bax is up-regulated during apoptosis in p53A cells (Han et al., 1996; Sabbatini et al., 1995b) . However, Bax induction may not be sucient for p53-dependent apoptosis. Bax null ®broblasts expressing the adenovirus E1A protein are still able to undergo p53-dependent apoptosis, although the response is less robust (McCurrach et al., 1997) . Furthermore, BRK cells expressing E1A and a mutant of p53 with deletion of the proline-rich region which retains the ability to up-regulate bax expression, is defective for apoptosis induction (Sakamuro et al., 1997) . Thus, bax induction is not sucient for apoptosis by p53. As a transcriptionally crippled p53 mutant is not capable of inducing apoptosis (Sabbatini et al., 1995b ), yet unidenti®ed genes that are transcriptionally regulated by p53 must play a role in implementing apoptosis. In light of this evidence, we screened a subtractive cDNA library for p53-inducible genes during p53-dependent apoptosis.
Cdc42, a member of the Rho/Rac family of small G proteins was isolated from this screen. Members of the Rho/Rac family of GTPases are signal mediators that regulate cytoskeletal changes, transcription, cell cycle control, and apoptosis (Hall, 1998; Johnson, 1999; Van Aelst and D'Souza-Schorey, 1997) . The small GTPases regulate these molecular mechanisms by cycling from the inactive GDP-bound state to the active GTP-bound form. The binding to GTP/GDP is regulated by interaction of the GTPases with GEFs, GDP dissociation inhibitors, and GAPs (Hall, 1998; Johnson, 1999; Van Aelst and D'Souza-Schorey, 1997) .
Cdc42 regulates signaling by binding to downstream eector proteins (Tapon and Hall, 1997) mainly through its CRIB domain (Burbelo et al., 1995) . Reports have shown that Cdc42 and its downstream eectors, PAK1-3 and JNK/SAPK, are involved in stress-activated apoptosis (Bazenet et al., 1998; Chuang et al., 1997) . The downstream events or the phosphorylation targets that promote stress-activated apoptosis are not known. Expression of the activated form of Cdc42 in Jurkat T lymphocytes (Chuang et al., 1997) as well as in rat sympathetic neurons (Bazenet et al., 1998) induce an apoptotic response. In this report, we have shown that p53 can indirectly activate the Cdc42 GTPase to induce apoptosis. Cdc42 recruits PAK1 and activates JNK1 to phosphorylate, and consequently inactivate, the anti-apoptotic Bcl-2 protein allowing p53-dependent apoptosis.
Results

Activation and localization of Cdc42 in the presence of wild-type p53
In order to identify novel p53-inducible genes during apoptosis, a subtractive cDNA library was made from primary BRK epithelial cell line, p53A, expressing the adenovirus E1A protein and a temperature-sensitive p53(val135) mutant (Debbas and White, 1993) . As previously reported, p53A cells express the temperature sensitive p53(val135) mutant in which p53 is in the wild-type conformation at the permissive temperature of 328C and in the mutant conformation at the nonpermissive temperature of 38.58C (Debbas and White, 1993) . Previous studies have shown that p53A cells incubated at the permissive temperature induced high levels of wild-type p53 protein and undergo massive p53-dependent apoptosis (Debbas and White, 1993; Han et al., 1996; Sabbatini et al., 1995a,b; Thomas and White, 1998) . A subtractive cDNA library was made from p53A cells expressing mutant p53 at 38.58C and from cells expressing wild-type p53 at 328C. Our aim was to identify genes that are transcriptionally up-regulated by wild-type p53 during apoptosis.
One of the genes identi®ed from this library screen was cdc42, a member of the small G protein family. Northern blot analysis of cdc42 in p53A cells incubated at 328C for 4 h showed a slight increase in cdc42 message when wild-type p53 was induced (Figure 1a) . p21
WAF1
, a known p53-inducible gene was up-regulated at this time interval (Figure 1a ). Competitive PCR analysis on cDNA from p53A cells incubated at 38.58C versus cells at 328C for 4 h showed a twofold increase in cdc42 message (data not shown). The small increase of cdc42 RNA was not observed when cycloheximide, a protein synthesis inhibitor, was present when p53 was induced (Figure 1a ), which indicated that transcriptional regulation of cdc42 by p53 was probably not direct.
We then examined Cdc42 protein expression in p53A cells incubated at the permissive temperature for various time intervals. Up-regulation of endogenous Cdc42 protein was observed in p53A cells (Figure 1b ) when wild-type p53 was induced (Debbas and White, 1993) . In contrast, Cdc42 protein was not induced in BRK cells expressing E1A and 22/23p53(val135) (Figure 1b) , a transcriptionally defective mutant of p53 (Sabbatini et al., 1995b) . Thus, cdc42 RNA and protein are induced by transcriptionally functional p53.
Since G-proteins are known to become membraneassociated upon activation (Boivin and Beliveau, 1995; Johnson, 1999) , we examined whether Cdc42 was present in the soluble or insoluble fractions during apoptosis. Soluble and insoluble lysates from p53A cells undergoing apoptosis during various time intervals were electrophoresed on SDS ± PAGE. Cdc42 protein appears to shift from soluble to the insoluble fraction as cell death progress (Figure 1c, upper panel) . There is less Cdc42 protein in Figure 1c , day 4 (soluble/insoluble) than in Figure 1b , day 4 because these are independent experiments using two dierent lysis buers, therefore, the results may have slight variations. These results suggest that Cdc42 may localize to membranes or cytoskeletal structures when apoptosis is induced in cells. We next wanted to determine whether Cdc42 was present in its active GTP-bound form in the presence of wild-type p53. To determine the state of Cdc42, we took advantage of an anity precipitation assay using the regulatory domain (residues 67 ± 150) of PAK1 (Benard et al., 1999) . The protein-binding domain of PAK1 functions as a potent anity ligand for the active small G proteins, Cdc42 and Rac. Soluble lysates from the p53A cells undergoing apoptosis were used to anity precipitate Cdc42-GTP. The precipitates were electrophoresed on SDS ± PAGE and blotted with a monoclonal antibody speci®c for Cdc42. The presence of Cdc42 in the precipitates indicates that it is in the active GTP-bound form. Surprisingly, our data shows that Cdc42 was in the active GTP-bound state (Figure 1c , lower panel), even in the presence of mutant p53. These results suggested that p53 expression might not aect the proportion of Cdc42 in the GTP form, but did lead to an increase in total Cdc42, which may in¯uence total amount of Cdc42-GTP.
Previous studies have shown that Cdc42 proteins are mostly membrane bound in the presence of GTPgS through their post-translational modi®cations (for example, farnesylation of the CAAX motif) and are localized to either internal membranes or plasma membranes (Boivin and Beliveau, 1995) . Therefore, we next wanted to determine the endogenous localization of Cdc42 during induction of wild-type p53. At the permissive temperature, Cdc42 appeared to translocate to the plasma membrane as cells undergo p53-mediated apoptosis (Figure 1d ). These results suggested that activated Cdc42 in the presence of wild-type p53 underwent post-translational modi®cations, which may promote translocation of Cdc42 to the plasma membrane. In addition, we have examined Cdc42 translocation in p53A cells stably expressing E1B 19K, an adenovirus protein that inhibits p53-mediated , and actin cDNAs were used as probes. (b) Western blot analysis of Cdc42 and actin in p53A and 22/23 cells incubated at 38.58C (day 0) and at 328C from day 1 to day 4. (c) Western blot of Cdc42 in soluble and insoluble lysates from p53A cells incubated at the nonpermissive temperature (day 0) and at the permissive temperature from day 1 to day 4 (upper panel). The soluble lysates were used for anity precipitation/Western blot of Cdc42 in p53A cells at 38.58C (day 0) and at 328C from day 1 to day 4 (lower panel). The protein binding domain (residues 67 ± 150) of PAK1 was used as an anity ligand for GTP-bound Cdc42 (Benard et al., 1999) . Negative (7) and positive (+) control represent HeLa extracts loaded with GDP or GTPgS, respectively. (d) Indirect immuno¯uorescence of Cdc42 in p53A incubated at 38.58C (day 0) and at 328C from day 1 to day 3 apoptosis (Debbas and White, 1993) . Translocation of Cdc42 to the plasma membrane was delayed in p53A cells expressing E1B 19K (data not shown). However, prolonged incubation of 19K expressing cells at 328C eventually induced translocation of Cdc42 to the plasma membrane (data not shown). These results suggest that Cdc42 translocation may be due to p53 activation and not a consequence of apoptosis.
Overexpression of Cdc42 promotes apoptosis, bypassing the requirement for wild-type p53
To investigate further the role of Cdc42 in p53-mediated apoptosis, we examined whether transient expression of Cdc42 can promote apoptosis in the absence of wild-type p53. For this assay, we used several mutants of Cdc42. As mentioned previously, Cdc42 is a GTPase where it is active when bound to GTP and inactive when bound to GDP. Therefore, we used two activated mutants of Cdc42, Cdc42V12 (valine substituted for glycine 12) and Cdc42L61 (leucine substituted for glutamine 61), and a dominant-negative mutant, Cdc42N17 (threonine substituted for asparagine 17), to determine its eects on cell viability. The activated Cdc42 mutants are constitutively GTP-bound due to their inability to hydrolyze bound GTP. In contrast, the dominant negative Cdc42 mutant is constitutively GDP-bound. Western blot analysis of p53A cells transiently transfected with Cdc42 mutant reveals equivalent expression (Figure 2a, upper panel) . Our results show that wild-type and the activated mutants of Cdc42 induced apoptosis in p53A cells at 38.58C (Figure 2a , lower panel). In contrast, the dominant-negative mutant of Cdc42 did not induce apoptosis ( Figure  2a , lower panel). These results suggested that overexpression of Cdc42 did induce cell death, bypassing the requirement for p53.
Since Cdc42 lies downstream of p53, we wanted to determine whether dominant-negative Cdc42 could inhibit p53-mediated cell death. Stable clones of p53A cells expressing dominant-negative Cdc42 or cells expressing vector alone were assessed for cell viability at the permissive temperature. Thirteen stable clones expressing various levels of Cdc42N17 and four vector control cell lines were established ( Figure 2b ). As shown in Figure 2c , nine out of 13 dominant-negative Cdc42 expressing stable clones were more resistant to p53-induced apoptosis. One out of the four vector controls was resistant to p53-dependent apoptosis. This variability may be due to clonal variation or genomic instability. A complete inhibition of cell death was not observed, probably due to the ability of p53 to induce apoptosis through other cascades, such as up-regulation of bax. Our results suggest that Cdc42 may be involved in one of the pathways in which p53 induces cell death.
PAK1 plays a role in p53-mediated apoptosis
The Bcl-2 family members are known inhibitors of apoptosis (Gross et al., 1999; Korsmeyer, 1995; White, 1996) . Therefore, we wanted to determine whether these inhibitors could block Cdc42-induced cell death. Proteins that bind to both Cdc42 and Rac include the serine/threonine kinases PAK1-3 (Dharmawardhane et al., 1997; Sells and Cherno, 1997; Zhao et al., 1998) . Binding of Rac-and Cdc42-GTP to PAKs leads to autophosphorylation and activation of this kinase, thus enabling it to phosphorylate substrates on serine/ threonine residues. In order to determine whether PAK1 plays a role in mediating apoptotic signal from Cdc42, we examined whether a dominant-negative form of PAK1 can block Cdc42wt-and Cdc42V12-mediated apoptosis. The dominant-negative form of PAK1 was constructed by substituting the active lysine 299 for an arginine in the kinase domain (Tang et al., 1997) . In addition to detecting the 58 kDa PAK1 band, Western blot analysis of ectopically expressed dominant-negative PAK1 revealed a background band of approximately 26 kDa (Figure 3a, upper panel) . Transient expression of dominant-negative PAK1 did indeed reduce Cdc42wt-and Cdc42V12-mediated apoptosis at 38.58C (Figure 3a , lower panel). Our results suggested that PAK1 might play a role in the apoptotic signal transduction cascade induced by Cdc42.
To con®rm this ®nding, we next examined whether p53A cells expressing a dominant-negative form of PAK1 can block p53-mediated apoptosis at the permissive temperature. Seven stable clones of p53A cells expressing dominant-negative PAK1 and three vector controls (Figure 3b ) were isolated and assessed for their ability to block p53-mediated apoptosis. Six out of seven dominant-negative PAK1 stable cell lines were signi®cantly more resistant to p53-mediated apoptosis than all of the three vector control cell lines (Figure 3c ). Our data indicated that dominant-negative PAK1 partially blocked p53-dependent apoptosis at the permissive temperature (Figure 3c) . Again, the incomplete inhibition of p53-mediated apoptosis by dominant-negative PAK1 was probably due to activation of more than one apoptotic pathway by p53 or by Cdc42. Our results suggested that Cdc42 might induce apoptosis in p53A cells through PAK1 kinase. Previous studies have shown that Rac1 and Cdc42 GTPases can eciently stimulate the c-Jun N-terminal kinases (JNKs) or stress-activated protein kinases (SAPKs) (Bagrodia et al., 1995; Coso et al., 1995; Minden et al., 1995) . Activation of these kinases can stimulate phosphorylation of transcriptional regulators such as c-Jun, ATF2, ELK and p53 (Fuchs et al., 1998; Gille et al., 1995; Gupta et al., 1995; Hu et al., 1997; Minden et al., 1995) . Studies have shown that the activated small GTPase Rac1 can induce phosphorylation of Bcl-2 through the JNK1 kinase pathway (Maundrell et al., 1997) . Furthermore, studies have suggested that phosphorylation of Bcl-2 inactivates its anti-apoptotic activity (Haldar et al., 1995) . Our data have shown that Bcl-2 was ineective at blocking Cdc42-mediated apoptosis at 38.58C (Figure 3a) . Therefore, we wanted to investigate whether Cdc42 could inactivate Bcl-2 by inducing phosphorylation through JNK1. Overexpression of activated Cdc42V12 mutant at 38.58C did not induce a mobility shift in Bcl-2, indicative of phosphorylation (Maundrell et al., 1997) on SDS ± PAGE (Figure 4a ). However, coexpression of Cdc42V12 and JNK1 at 38.58C induced a mobility shift of Bcl-2 on SDS ± PAGE (Figure 4a ). These results may indicate post-translational phos- Maundrell et al., 1997) . In contrast to the activated Cdc42V12 mutant, overexpression of dominant-negative Cdc42N17 mutant along with JNK1 at 38.58C did not induce mobility shift of wild-type Bcl-2 (Figure 4a ). Furthermore, coexpression of Cdc42V12 mutant with Bcl-X L did not induce a mobility shift of Bcl-X L on SDS ± PAGE (data not shown). In order to determine whether the mobility shift was indeed Bcl-2 phosphorylation, we mutated all the known phosphorylation sites of Bcl-2 (Maundrell et al., 1997) . Serines 70, 87 and/or threonines 56, 74 of Bcl-2 were substituted for alanines, rendering Bcl-2 resistant to phosphorylation (Maundrell et al., 1997) . Mobility shift of Bcl-2 double mutants S70,87A and T56,74A, was still observed, when expressed with Cdc42V12 and JNK1 (Figure 4a ). However, mobility shift of Bcl-2 quadruple mutant, S70,87A,T56,74A, was consistently decreased (Figure  4a ), indicating that the mobility shift may indeed represent phosphorylation of Bcl-2. Our functional studies of Bcl-2 indicated that the degree of phosphorylation correlated well with Bcl-2's ability to block Cdc42-induced cell death. Bcl-2 T56,74A mutant, which retained its ability to be phosphorylated, was not able to inhibit Cdc42-induced cell death ( Figure  4b ). However, the Bcl-2 S70,87A mutant, which was decreased in its phosphorylation, was a better inhibitor of Cdc42-induced cell death than wild-type Bcl-2. The Bcl-2, S70,87A,T56,74A quadruple mutant, which was resistant to phosphorylation, was able to eciently block Cdc42-induced apoptosis (Figure 4b ). The Bcl-2 mutants that are unable to be phosphorylated can block Cdc42-induced apoptosis more eciently than wild-type Bcl-2. These results suggested that Cdc42-activated JNK1 phosphorylation of Bcl-2 inactivated its anti-apoptotic function, thereby promoting cell death. Previous studies have demonstrated that Bcl-2 gene expression is repressed in the presence of wild-type p53 (Miyashita et al., 1994a,b) . We have found that Bcl-2 mRNA is slightly repressed in the presence of wild-type p53 using oligonucleotide microarray technology (Cuconati and White, unpublished observations). Unfortunately, we were not able to detect Bcl-2 protein in p53A at 328C due to the unavailability of a ratspeci®c Bcl-2 antibody. Nonetheless, we have previously observed that either stable expression of Bcl-2 or E1B 19K can block p53-dependent apoptosis (Chiou et al., 1994; Han et al., 1996) . However, unlike E1B 19K, Bcl-2 protection is not long-lasting (Sabbatini et al., 1995a) . The protection observed by Bcl-2 diminishes as p53-dependent cell death progresses. In contrast, E1B 19K protects cells from p53-dependent apoptosis as long as the death stimuli persist, perhaps because 19K function has not been found to be regulated by phosphorylation (McGlade et al., 1989) . To examine more closely the role of Bcl-2 phosphorylation in p53-mediated cell death, we made stable p53A cells expressing wild-type Bcl-2 or the quadruple mutant of Bcl-2 (S70, 87A, T56, 74A). All the stable cell lines express comparable levels of the exogenous Bcl-2 protein (Figure 4c ). Cell viability of the stable lines was assessed at the permissive temperature. Cells expressing both forms of Bcl-2 were resistant to the initial stages of p53-dependent apoptosis. However, viability was decreased in all three clones expressing wild-type Bcl-2 after prolonged incubation at 328C (Figure 4d,e) . In contrast, two out of three clones expressing Bcl-2S70,87A,T56,74A quadruple mutants were remarkably resistant to prolonged incubation at the permissive temperature (Figure 4d,e) . These results suggest that Bcl-2 may be inactivated during p53-dependent apoptosis by being phosphorylated, possibly by JNK1. Unfortunately, the lack of a good antibody that recognizes rat Bcl-2 prevents us from determining the status of endogenous Bcl-2 during p53-mediated apoptosis in p53A cells. Nevertheless, our model suggests a mechanism whereby Bcl-2 inactivation promotes p53-dependent cell death.
Discussion
The tumor suppressor p53 is known to transcriptionally regulate several genes involved in cell cycle arrest and apoptosis (Ko and Prives, 1996; Levine, 1997) . In this study, we have shown that p53 not only upregulates Bax, it can indirectly regulate Cdc42 GTPase. Although cdc42 transcript was only marginally up-regulated by p53, Cdc42 protein was substantially induced in the presence of wild-type p53 ( Figure 5 ). Our results demonstrate that Cdc42 was found in its GTP-bound active form, even in the presence of mutant p53. However, cytosolic Cdc42 was translocated to the plasma membrane when wildtype p53 was activated ( Figure 5 ). Therefore, we propose that increased protein levels and translocation of Cdc42 to the plasma membrane are probably more crucial in propagating the apoptotic signal induced by p53.
The small G proteins have been shown to induce apoptosis in lymphocytes (Gulbins et al., 1996) as well as in neuronal cells (Bazenet et al., 1998) . In our system, Cdc42 GTPase was a potent inducer of apoptosis. The morphological changes during apoptosis were observed within 12 h after overexpression of activated Cdc42 mutant. Since a prominent role of Cdc42 is to eect changes in the cytoskeletal structures within cells (Hall, 1998) , we cannot exclude the possibility that Cdc42 may induce cytoskeletal changes in dying cells, which probably contributes to its potency as pro-apoptotic regulator. A dominantnegative mutant of Cdc42 was not able to completely block p53-mediated apoptosis, probably due to other pathways being utilized by p53 to induce cell death. The pro-apoptotic Bax protein is directly up-regulated by p53 (Miyashita and Reed, 1995) . Induction of Bax promotes cytochrome c release from the mitochondria, which is inhibited by anti-apoptotic Bcl-2 family members (RosseÂ et al., 1998) ( Figure 5 ). Bax facilitates the release of cytochrome c from the mitochondria, thereby initiating activation of caspases during p53-dependent cell death ( Figure 5 ). However, Bax induction is not sucient for apoptosis by p53 (McCurrach et al., 1997; Sakamuro et al., 1997) . Therefore, blocking one pathway would not be sucient for complete inhibition of cell death ( Figure  5) . Furthermore, previous studies have shown that caspase inhibitor, z-VAD, inhibits p53-mediated apoptosis , thereby suggesting that caspase activation lies downstream of p53 ( Figure 5 ). Our data concerning p53 induction of Cdc42 is consistent with the observation that z-VAD blocks p53-dependent cell death.
Our data demonstrated that PAK1 might be activated downstream of Cdc42 ( Figure 5 ). However, p53-dependent apoptosis was not completely inhibited by dominant-negative PAK1. These results indicate that: (1) there are other pathways for p53 to induce apoptosis and (2) there may be other substrates utilized by Cdc42 to induce apoptosis. Reports have shown that PAK1 is activated by caspase-3 during apoptosis (Walter et al., 1998) . Furthermore, caspase-3 is known to be activated during p53-mediated apoptosis . In light of this evidence, it is possible that PAK1 activation will be an indirect consequence of apoptosis, and not direct activation by Cdc42. PAKs are well known substrates of Cdc42. However, some proteins are more speci®c for Cdc42 such as the activated Cdc42-associated tyrosine kinases (ACK) (Manser et al., 1993; Yang and Cerione, 1997) and the Wiscott-Aldrich-syndrome proteins (WASP) (Aspenstrom et al., 1996; Symons et al., 1996) . We cannot rule out the possibility that these proteins may also be part of the pathway whereby Cdc42 induces cell death ( Figure 5 ).
Other small G proteins such as Rac 1 and Rho may play a role in p53-mediated apoptosis. In our hands, an activated Rac 1 mutant was not as ecient as the activated Cdc42 mutant in inducing apoptosis (data not shown). However, it has been shown that activated Rac 1 can induce JNK1 phosphorylation of Bcl-2 (Maundrell et al., 1977) . In addition, Rac 1 has been shown to mediate Fas-induced apoptosis in lymphocytes (Gulbins et al., 1996) . It remains possible that other small G proteins will also play a role in p53-dependent apoptosis. Recent reports have identi®ed small GTPases and factors associated with this family of proteins, such as rhoHP1, Cdc42Hs kinase Ack, and Ral, a GDP dissociation stimulator, as p53-regulated gene products (Zhao et al., 2000) . This study further supports our data that the small G protein Cdc42 plays a role in the p53 pathway.
Phosphorylation of Bcl-2 has been shown to inactivate (Haldar et al., 1995) and activate (May et al., 1994 ) the anti-apoptotic activity of Bcl-2. Since Bcl-2 did not protect cells from Cdc42-mediated apoptosis, whereas Bcl-X L and E1B 19K did, we investigated whether phosphorylation of Bcl-2 can inactivate it in the Cdc42 pathway. Four putative Ser/Thr kinase phosphorylation sites (Ser70, Ser87, Thr56, Thr74) in the N-terminal loop region of Bcl-2 have been reported (Maundrell et al., 1997) . The number of sites phosphorylated by JNK1 probably depends on the intensity of kinase activation. Our data demonstrate that mutating all four sites to alanine decreased Bcl-2 phosphorylation. Although with poor resolution, we have observed metabolic 32 P-labeling of Bcl-2 in p53A cells expressing wild-type Bcl-2, but not Bcl-2 quadruple mutant, when cotransfected with Cdc42V12 and JNK1 (data not shown). The phosphorylated form of Bcl-2 may less eciently interact with the proapoptotic protein Bax, therefore, Bax may be free of any antagonistic stimuli ( Figure 5 ). Our data using the Bcl-2 quadruple mutant stable cell lines indicate that Bcl-2 phosphorylation is important for inactivating its antiapoptotic activity. We did, however, observe that one Bcl-2 quadruple mutant cell line (Bcl-2 mut-24) was sensitive to p53-dependent apoptosis, which may be due to genomic instability. For this reason, we have examined several Bcl-2 quadruple mutant stable lines and for the most part, they are truly resistant to p53-dependent apoptosis. However, it is important to emphasize that Cdc42 is not the only target for p53 and Bcl-2 may not be the only target of Cdc42 ( Figure  5 ). Furthermore, other kinases including Raf (Blagosklonny et al., 1996) , PKCa (Ruvolo et al., 1998) , ERK (Deng et al., 2000) , and Cdc2 (Furukawa et al., 2000) have been shown to phosphorylate Bcl-2. We have not examined the role of these kinases in Cdc42-mediated apoptosis. Therefore we cannot exclude the possibility that one or more of these kinase may play a role in phosphorylation of Bcl-2 during p53-dependent apoptosis.
Threonine 69 in the loop region of Bcl-2 has also been shown a substrate for JNK1 (Yamamoto et al., 1999) . This is likely because our data when using the quadruple mutant of Bcl-2 occasionally displayed a slight mobility shift on SDS ± PAGE, suggesting the existence of other phosphorylation site(s). Therefore, it is possible that threonine 69 may be another target site for JNK1. Recent reports have shown that Bcl-2 is phosphorylated during the G2/M phase of the cell cycle (Yamamoto et al., 1999) . Serine 70 was observed to be the major phosphorylation site during G2/M (Yamamoto et al., 1999) . The many phosphorylation sites of Bcl-2 may be dierentially regulated by more than one kinase for dierent cellular processes. ASK1 and MKK7 have been shown to activate JNK1 leading to Bcl-2 phosphorylation (Yamamoto et al., 1999) . It is likely that these kinases may be involved in JNK1 activation in our system. However, our data using dominantnegative Cdc42 show a complete inhibition of Bcl-2 phosphorylation, which strongly suggests a role for Cdc42 in the activation of JNK1 ( Figure 5 ). In addition, recent reports have shown that JNK kinases are crucial in inducing apoptosis during DNA damage (Tournier et al., 2000) . Primary murine embryo ®broblasts with targeted disruptions of JNK kinases were resistant to DNA damage induced by UV radiation. These reports support the idea that JNK kinases play a role in p53-dependent apoptotic pathway. Finally, JNK1 has been shown to phosphorylate p53, thereby increasing its transcriptional activity (Fuchs et al., 1998; Hu et al., 1997) . This study raises the possibility that other substrates may exist for JNK1 in our system. An intriguing hypothesis is that phosphorylation of p53 by JNK1 is a positive feedback loop whereby p53's ability to transcribe genes required for apoptosis is enhanced.
Materials and methods
Cell lines and culture conditions
Primary Fisher baby rat kidney (BRK) epithelial cells prepared from 6 day old baby rats were cultured in Dulbecco's modi®ed eagle medium (DMEM, Life Technologies, Grand Island, NY, USA) with 5% fetal calf serum (Gemini BioProducts, Woodland, CA, USA) as described previously (White et al., 1992) . The transformed BRK cell line, p53A, was derived from transfection of primary BRK cells with plasmids encoding E1A (pCMVE1A) and the temperature sensitive mutant p53(val135) (pLTRcGval135) (Debbas and White, 1993) . The temperature sensitive p53 mutant is in the mutant conformation at the nonpermissive temperature of 38.58C and is in the wild-type conformation at the permissive temperature of 328C. The 22/23p53(val135) cell line was generated from primary BRK cells transformed with adenovirus E1A and p53(22 ± 23val135) (Sabbatini et al., 1995b) . p53(22 ± 23val135) was generated from p53(val135) by mutating amino acids 22 and 23 which renders the protein transcriptional defective and apoptosis defective at the permissive temperature (Sabbatini et al., 1995b) .
PCR-select cDNA subtraction cDNA was synthesized from 1 mg of poly(A) + RNA from p53A cells at the nonpermissive temperature (38.58C) and 4 h at the permissive temperature (328C). The cDNA at the nonpermissive temperature was used to subtract from cDNA at the permissive temperature through several steps of hybridization and PCR ampli®cation according to manufacturer's instructions (ClonTech, Palo Alto, CA, USA). Thus, the subtracted cDNA library enriches for p53-inducible genes, which are up-regulated after 4 h of incubation at the permissive temperature. Plasmids pRK5cdc42wt, pRK5cdc42L61, and pRK5cdc42N17 expression plasmids that encode for wild-type Cdc42, constitutively activated form of Cdc42 and dominant-negative form of Cdc42, respectively, were generous gifts from Dr A Hall (MRC, London, UK). Dr L Van Aelst (Cold Spring Harbor Laboratories, NY, USA) provided pCGcdc42V12 expression plasmid, which encodes for a constitutively activated form of Cdc42. pcDNA3.1cdc42N17 used for stable transfection was constructed by subcloning pRK5cdc42N17 into pcDNA3.1 using BamH1 and EcoR1 sites. pcDNA3E1B19K, pCMVE1A and pLTRcGval135 were previously described (Debbas and White, 1993; Sabbatini et al., 1995a,b) . Dr C Thompson (University of Pennsylvania, Philadelphia, PA, USA) provided pcDNA3Flag-Bcl-x L , and Dr JS Gutkind (NIH, Bethesda, MD, USA) provided pcDNA3HA-JNK1. Dr C Gelinas (CABM/UMDNJ, Piscataway, NJ, USA) provided pcDNA3.1Bcl-2wt. pcDNA3.1HisLacz was purchased from Invitrogen (Carlsbad, CA, USA). pcDNA3-PAK1 and pcDNA3dominant-negative PAK1, pcDNA3.1Bcl-2S70,87A, pcDN3.1Bcl-2T56,74A, and pcDNA3.1Bcl-2S70,87A,T56,74A were constructed as described below.
Northern blot analysis
Cytoplasmic RNA was extracted from p53A cells using the NP-40 lysis protocol as previously described (Muraoka et al., 1996) . Cytoplasmic RNA (30 mg) was loaded onto a formaldehyde gel and blotted overnight using Hybond-N membranes (Amersham Pharmacia BioTech, Piscataway, NJ, USA) for transfer. The membrane was hybridized with a random-primed a-32 P-dATP labeled cdc42, p21 WAF1 or actin cDNA probe in ExpressHyb Hybridization solution (ClonTech, Palo Alto, CA, USA) at 658C overnight. Blots were washed in 0.16SSC and 0.1% SDS at 508C and exposed to ®lm overnight.
Mutagenesis of PAK1 and Bcl-2 PAK1 was PCR cloned from a HeLa cDNA library. The plasmid was constructed by 3-fragment ligation of pcDNA3 (cut with KpnI and EcoRI), FLAG-tag fragment (KpnI and XmaI), and PAK1 PCR fragment (cut with XmaI and EcoRI). The dominant-negative form of PAK1 was constructed by substituting the active lysine 299 in the kinase domain for an arginine by PCR mutagenesis using the Stratagene (La Jolla, CA, USA) QuikChange Site-directed Mutagenesis Kit according to manufacturer's recommendations. The sense primer used was 5'-AGGAGGTGGCCATT-CGGCAGATGAATCTTCA-3' and the antisense strand was 5'-TGAA GATT CAT CTG CCGA AT GG CC ACC TCCT-3' (Tang et al., 1997) .
The Bcl-2 phosphorylation mutants were constructed using the following strategy: a 5' primer along with a mutagenic primer was used to PCR amplify parts of Bcl-2 with the speci®c mutation. The PCR product was run on a 1% agarose gel and puri®ed using the Qiagen DNA puri®cation kit (QIAEX II, Qiagen, Valencia, CA, USA) according to manufacturer's recommendations. This PCR product containing the desired mutation was then used as a 5' primer along with a 3' primer to amplify the entire Bcl-2 cDNA with the respective mutations. This 878 bp mutated Bcl-2 PCR product was gel puri®ed and ligated into the TA cloning vector pcDNA3.1-V5/His (Invitrogen, Carlsbad, CA, USA). For the single mutations, wild-type Bcl-2 in pcDNA3.1 was used as the DNA template in PCR. For the double mutant Bcl-2S70,87A, the DNA template was pcDNA3.1V5/HisBcl-2S70A. The triple mutant T56A,S70,87A was made by using pcDNA3.1V5.HisBcl-2S70,87A, as the DNA template in PCR with mutagenic primer T56A. This triple mutant was then used as the DNA template in PCR to generate quadruple mutant T56,74AS70,87A with the mutagenic primer S70A,T74A.
The Bcl-2 5' sense primer used with a HindIII site was 5'-GAGAAGCTTGTGCCGTTGGCCCCC-3' and the 3' antisense primer with an XbaI site used was 5'-GGTTCTAGAA-CAGCCTGCAGCTTT-3'. The following primers were used for mutagenesis: for S70A, 5'-GGTCGCCAGGACCGCGC-CACTACAGACCC-3', for S87A, 5'-CCTGCGCTCGCCCC-GGTGCCACC-3' , for T56A, 5'GCCCGGGCACGCGCCC-CATCCAGC-3', for T74A, 5'-CCTCGCCACTACAGGCC-CCGGCTGC-3', and for S70A and T74A: 5'-CCGCGCCA-CTACAGGCCCCGGCTGC-3'.
Stable and transient transfection
For stable transfections, p53A cells were electroporated (220 V, 950 mF) with 1 mg of pcDNA3.1, pcDNA3. 1cdc42N17, pcDNA3dominant-negativePAK1, pcDNA3. 1Bcl-2, or pcDNA3.1Bcl-2S70,87A,T56,74A, along with 10 mg of salmon sperm DNA. Cells were selected 48 h posttransfection in DMEM containing 0.5 mg/ml G418 (Life Technologies, Grand Island, NY, USA) for 14 days. Individual colonies were cloned using cloning cylinders and expanded into cell lines. For transient transfections, cells were electroporated with 8 or 10 mg of plasmid DNA and 2.7 or 3.3 mg, respectively, of pcDNA3.1HisLacZ. Cells were assayed for viability 24 h post-transfection as described below and whole cell lysates were made for monitoring protein expression. For Cdc42 transient transfections, 8 mg of pRK5cdc42wt, pRK5cdc42L61, pCGcdc42V12, and pRK5 cdc42N17 were electroporated into p53A cells. Ten mg of pcDNA3E1B19K, pcDNA3Flag-Bcl-x L , pcDNA3HA-JNK1, pcDNA3.1Bcl-2wt, pcDNA3.1Bcl-2S70,87A, pcDN3.1Bcl-2T56,74A, and pcDNA3.1Bcl-2S70,87A,T56,74A were electroporated into p53A cells.
Cell viability assays
Cell viability was measured by trypan blue (Life Technologies, Grand Island, NY, USA) staining. Cell were trypsinized, centrifuged, resuspended in PBS, and counted using a hemocytometer after diluting in trypan blue. b-galactosidase staining was also performed to determine cell viability in cells cotransfected with pcDNA3.1HisLacZ. Cells were ®xed in 1% glutaraldehyde (Sigma, St. Louis, MO, USA) for 15 min at room temperature, and stained with X-gal (Roche Diagnostics, Indianapolis, IN, USA) for b-galactosidase activity. Blue cells were counted as an indicator of viable cells.
Indirect immunofluorescence
Cells were ®xed in 7108C methanol for 10 min and washed in PBS before incubation with primary antibodies. After a few washes in PBS, cells were incubated with rhodamineconjugated goat anti-rabbit antibody (Jackson Labs, Bar Harbor, ME, USA). Cells were then washed, mounted, and analysed by¯uorescence microscopy using Nikon FXA epi¯uorescence microscope (Micron Optics, Parsipanny, NJ, USA).
Western blot analysis
Cell lysates were made by lysing in 26 Laemmli buer containing 4% SDS and 5% b-mercaptoethanol. Equal amounts of protein (20 or 30 mg) were electrophoresed on 15 or 17% SDS-polyacrylamide gels and transferred to PVDF membranes (Millipore, Bedford, MA, USA). Membranes were blocked for 15 min at room temperature in 5% nonfat Carnation dry milk in PBS containing 0.1% Tween-20 (PBST). Membranes were incubated with primary antibody followed by washes in PBST and then incubated with horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG or donkey anti-rabbit IgG (Amersham Pharmacia Biotech, Piscataway, NJ, USA) at 1 : 2000 dilution. After several washes, the blots were developed using the ECL chemiluminescence detection kit according to manufacturer's instructions (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Affinity precipitation
PAK1 binding domain (residues 67 ± 150) was immobilized on agarose beads and used as an anity ligand for GTPbound Cdc42 according to manufacturer's protocol (Upstate Biotechnology, Lake Placid, NY, USA). Brie¯y, p53A cells were incubated at 38.58C (day 0) and at 328C from day 1 to day 4 and were lysed in 25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10 mM MgCl 2 , 1 mM EDTA, and 2% glycerol in the presence of 10 mg/ml leupeptin, 10 mg/ml aprotinin, 25 mM sodium¯uoride and 1 mM sodium orthovanadate (Benard et al., 1999) . The insoluble material was removed by centrifugation. The supernatant represents the soluble fraction, which was used for the anity precipitation, and the pellet represents the insoluble fraction. The soluble fraction was incubated with PAK1 agarose beads for 60 min at 48C. The beads were washed several times and resuspended in 26 Laemmli sample buer and electrophoresed on a 17% SDS ± PAGE. Western blot analysis of Cdc42 was performed as mentioned above.
Antibodies
An anti-human Bcl-2 hamster antibody (BD Pharmigen, San Diego, CA, USA) was used at 1 : 1000 dilution to detect the transfected human Bcl-2 on Western blots. A polyclonal antiCdc42 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used at 1 : 200 dilution for Westerns and at 1 : 50 dilution for indirect immuno¯uorescence to detect rat Cdc42 protein and a mouse monoclonal anti-actin antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was used at 1 : 1000 dilution to detect actin on Western blots.
